Abstract: Methods of treating various types of cancer, including breast cancer, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C Motif Chemokine Receptor 4 immunotoxin alone or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an anti-programmed death-1 monoclonal antibody.

Abstract: Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.

Abstract: IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25.sup.+ and/or CCR4.sup.+ cutaneous T cell lymphoma, and other human CD25.sup.+ or CCR4.sup.+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25.sup.+ or CCR4.sup.+ Tregs.

Abstract: The present application disclosure a method A method and device for controlling a compass bird. The method includes: a main control single-chip microcomputer entering a first deep sleep mode when not processing a task; the main control single-chip microcomputer switching from the first deep sleep mode to a first working mode after receiving an external interrupt signal; a peak detection circuit detecting whether there is a communication carrier signal; a data demodulation unit not starting if the peak detection circuit detects that there is no communication carrier signal; and the data demodulation unit starting to demodulate the communication carrier signal if the peak detection circuit detects that there is the communication carrier signal, and a communication demodulation module sending a demodulated signal to the main control single-chip microcomputer.

Abstract: A suction unit is described for a hand-held suction apparatus. The suction unit creates a suction air flow to suck up dirt particles. The suction unit has a housing with a rear wall and a hand grip arranged on the rear wall such that the hand grip and the rear wall border a cut-out for a user to arrange fingers of a hand when gripping the hand grip. The suction unit has an electrically operated display element on the rear wall of the housing facing the cut-out so as to output visual information. The display element has a first part-display which is arranged on a first side of the hand grip and a second part-display which is arranged on a second side of the hand grip lying opposite the first side. The display element is configured such that the first and second part-displays display the same visual information.

Abstract: IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25+ and/or CCR4+ cutaneous T cell lymphoma, and other human CD25+ or CCR4+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25+ or CCR4+ Tregs.

Abstract: This disclosure relates to immunotoxin fusion proteins that comprise a bivalent single-chain fragment variable that specifically binds to the thrombopoietin receptor (cMPL); and a diphtheria toxin. The disclosure also provides compositions comprising such proteins and nucleic acid molecules encoding such proteins and uses thereof.

Abstract: The present disclosure provides a vector generation method, a data processing method, a vector generation apparatus, a data processing apparatus, and a non-transitory computer-readable storage medium. The vector generation method includes: performing learnable processing on N current position vectors in a mapping table to obtain N learnable position vectors, where N is a positive integer; and updating the N current position vectors with the N learnable position vectors.

Abstract: According to implementations of the present disclosure, a method, apparatus, device and medium for managing molecular prediction is provided. In the method, an upstream model is obtained from a portion of network layers in a pretrained model, the pretrained model describing an association between a molecular structure and molecular energy. A downstream model is determined based on a molecular prediction purpose, and an output layer of the downstream model is determined based on the molecular prediction purpose. A molecular prediction model is generated based on the upstream model and the downstream model, the molecular prediction model describing an association between a molecular structure and a molecular prediction purpose associated with the molecular structure. Since the upstream model may have extensive knowledge related to molecules, the amount of training data required to train the molecular prediction model that is generated based on the upstream model and the downstream model may be reduced.

Abstract: Bivalent epidermal growth factor (EGF) fusion toxin including two EGF domains are provided. The described fusion toxin demonstrates increased binding and cytotoxicity when compared to a fusion toxin having a single EGF binding domain (monovalent). Methods for treating epidermal growth factor receptor (EGFR)-positive cancers and related materials are also provided.

Abstract: Embodiments disclosed herein relate to compositions and methods for inducing transplantation tolerance using immunomodulation agents. In certain embodiments compositions and methods disclosed herein, concern administering a composition including, but not limited to, anti-CD3 immunotoxin and administering a composition including, but not limited to, peripheral blood cells obtained from a donor of an organ, tissue or cells to be transplanted. In some embodiments, compositions and methods disclosed here can be used for modulating B- and/or T-cell-mediated immunity and/or rejection by reducing or eliminating anti-donor antibody production. Other embodiments concern modulating T-cell production in a subject preparing for, undergoing organ, tissue or cellular transplantation; or having or expected of developing GvHD for reducing the risk of, preventing or treating rejection or GvHD. In certain embodiments, combination compositions of anti-CD3 immunotoxin and peripheral blood cells from a donor are contemplated.

Abstract: Curative and prophylactic therapies for microvascular and/or macrovascular thrombosis are provided, as are prophylactic therapies capable of preventing fibrinolysis shutdown and therapies for non-thrombotic disorders. Methods provide for administering a therapeutically effective amount of an annexin A2.

Abstract: IL2-CCR4 bispecific immunotoxin, CCR4-IL2 bispecific immunotoxin, and methods of use thereof for treatment of refractory and recurrent human CD25+ and/or CCR4+ cutaneous T cell lymphoma, and other human CD25+ or CCR4+ tumors. The bispecific immunotoxin can be also used for broad cancer treatment via depleting CD25+ or CCR4+ Tregs.

Abstract: Mutant forms of human CTLA4, and their use, e.g., in xenotransplantation.

Abstract: IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.

Abstract: This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them.

Abstract: Anti-human chemokine (C—C motif) Receptor 4 immunotoxins and methods of use thereof, e.g., for depleting Tregs as an immunotherapy for the treatment of cancer; for the treatment of cancers associated with CCR4+ tumor cells such as skin homing cutaneous T cell lymphoma, adult T cell leukemia/lymphoma, and acute T-cell lymphoblastic leukemia; and for the depletion of CCCR4+ Th2 cells for the treatment of allergy-related conditions such as asthma.

Abstract: Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in Pichia pastoris, purified Annexin A2 produced by those methods, and methods of using the Annexin A2.

Abstract: IL-2 fusion toxins, e.g., bivalent-IL2 fusion toxins, and methods of use thereof.

Abstract: Mutant forms of human CTLA4, and their use, e.g., in xenotransplantation.